Oragenics Acquires Noachis Terra Inc., to Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein”

UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced its acquisition of UF Innovate | The Hub resident client Noachis Terra Inc., following its entry into a stock purchase agreement, to develop and commercialize TerraCoV2, a vaccine candidate which could provide specific immunity from the novel coronavirus (SARS-CoV-2), the root cause of COVID-19.

Noachis Terra Inc., a new biotechnology company that will focus its efforts on the development of a vaccine for COVID-19, holds a worldwide, nonexclusive license to the TerraCoV2 vaccine candidate from the National Institute of Allergy and Infectious Diseases (NIAID), an institute within the National Institute of Health (NIH). The company’s acquisition of Noachis Terra and its TerraCoV2 immunization product candidate represents its first step towards accessing pioneering technologies to reduce the global threat posed by COVID-19, which aligns with the company’s existing anti-infective programs.

Learn more about Oragenics Acquires Noachis Terra Inc., to Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein.”